Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of DWP14012 (Fexuprazan) in Healthy Japanese, Caucasian, and Korean Subjects
NCT03574415Phase 1Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fexuprazan in gastroesophageal reflux disease (GERD) (8 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration (Cmax) at 11 days, Steady State Cmax and Cmin at 1 day and 4 more. Started Nov 2018; status: completed.
02
Drugs
fexuprazan
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03574415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03574415.